Paper Published by USRM Chief Science Officer in Journal of Medical Cases
| SUNRISE, Fla., Oct. 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully used autologous stem cells from fat tissue to repair decubitus ulcers.
A decubitus ulcer is a wound on the skin also known as a pressure ulcer which typically occurs over bony skin, such as buttocks. These wounds can be common in spinal cord injury patients with limited mobility. The number of patients with pressure ulcers is estimated to be between 1.3 to 3 million in the United States. The number of hospitalizations as a result of decubitus ulcers has increased by more than 75% between 1993 and 2006. “We continue to identify beneficial ways to utilize our own healing stem cells retrieved from fat tissue for therapeutic use,” said Dr. Kristin Comella, USRM’s Chief Science Officer and author of the paper, “and decubitus ulcers are an important market given the aging baby boomer demographic. The elegance and simplicity of this effective therapy cannot be overstated. It’s an incredible opportunity to utilize a patient’s own cells to repair tissue damage without the use of drugs.” Non-healing decubitus ulcers can be challenging to treat and may often progress to other life-threatening complications. Significant tissue damage is present in stage three/four wounds and treatment options can be limited or present additional risks. Applications of regenerative medicine and stem cell therapy are rapidly expanding in particular in the field of non-healing wounds. Adipose tissue is a rich source of autologous stem cells which can be easily isolated in an outpatient visit. The paper documents a 49-year-old male with prior incomplete spinal cord injury with Stage 3 decubitus ulcer on the buttocks. The wound had persisted for 8 months with full thickness loss of epidermis and no exposure of underlying bone, muscle or tendon. Prior interventions include wound cleansing with hydrogen peroxide, wound dressing with Eusol (bleach, boric acid, and water) and gauze, and pressure relief by changing of position in bed. The patient’s autologous cells were injected directly into the ulcer. The wound was monitored and tracked with imaging and the patient was tracked for quality of life parameters as well as safety (adverse events). No complications or other safety events were reported either during the procedure or in the months following the procedure. The patient reported reduction of pain consistent with wound healing and a willingness to repeat therapies if required. The healing stage 3 pressure injury showed clear re-epithelialization. USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics. For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids. U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world. Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov. Media Contact: U.S. Stem Cell, Inc.
SOURCE U.S. Stem Cell, Inc. |
Company Codes: OTC-PINK:USRM |
View original content to download multimedia:
